According to Dr. Alex Morgan, Principal at Khosla Ventures and Dr. Melanie Matheu, Prellis Biologics’ co-founder and CEO, “Regenerative medicine has made enormous leaps in recent decades. However, to create complete organs, we need to build higher-order structures like the vascular system. Prellis’ optical technology provides the scaffolding necessary to engineer these larger masses of tissues. With our investment in Prellis, we’re supporting an initiative that will ultimately produce a functioning lobe of the lung, or even a kidney, to be used in addressing an enormous unmet global need.
The human tissue engineering is the ability to build complex tissues with working vascular systems. The future of regenerative medicine revolves around harnessing the power of our own cells as therapeutics and building the tissues to keep them alive. Khosla Ventures is the perfect investor to support our merging of deep tech and cutting-edge regenerative medicine. With this technology in hand, we can begin to ask questions about real 3D cell biology that have never been asked before.”
This entry was posted in 3D Print Biotechnology and Neuroscience., 3D Printed food., 3D Printed parts to save money., 3D Printing hobby products and design., 3D Printing Ideas, Patent. Fans of the day., 3D Printing industry news., 3D Printing Market share., Managing health with 3D printing., SV3DPrinter.com Policy. and tagged Biotech Showcase in San Francisco., Dr. Alex Morgan, Dr. Melanie Matheu, Khosla Ventures ', Prellis Biologics has raised $8.7M, Prellis Biologics', Regenerative medicine, vascular system.